VIDEX EC Drug Patent Profile
✉ Email this page to a colleague
When do Videx Ec patents expire, and when can generic versions of Videx Ec launch?
Videx Ec is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in VIDEX EC is didanosine. There is one drug master file entry for this compound. Additional details are available on the didanosine profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VIDEX EC?
- What are the global sales for VIDEX EC?
- What is Average Wholesale Price for VIDEX EC?
Summary for VIDEX EC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 124 |
| Patent Applications: | 3,859 |
| Drug Prices: | Drug price information for VIDEX EC |
| What excipients (inactive ingredients) are in VIDEX EC? | VIDEX EC excipients list |
| DailyMed Link: | VIDEX EC at DailyMed |
Paragraph IV (Patent) Challenges for VIDEX EC
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VIDEX EC | Delayed-release Capsules | didanosine | 200 mg, 250 mg and 400 mg | 021183 | 1 | 2004-06-01 |
US Patents and Regulatory Information for VIDEX EC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-001 | Oct 31, 2000 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-004 | Oct 31, 2000 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-002 | Oct 31, 2000 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-003 | Oct 31, 2000 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VIDEX EC
See the table below for patents covering VIDEX EC around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 96325 | ⤷ Start Trial | |
| Australia | 570853 | ⤷ Start Trial | |
| Australia | 5832990 | ⤷ Start Trial | |
| Australia | 6196886 | ⤷ Start Trial | |
| Canada | 1269044 | INHIBITION DE L'INFECTIVITE IN VITRO ET DE L'EFFET CYTOPATHIQUE DU VIRUS HTLV-III/LAV PAR LA 2'3'-DIDEOXYINOSINE, LA 2'3'-DIDEOXYGUANOSINE OU LA 2'3'-DIDEOXYADENOSINE (INHIBITION OF IN VITRO INFECTIVITY AND CYTOPATHIC EFFECT OF HTLV-III/LAV BY 2'3'-DIDEOXYINOSINE, 2'3' - DIDEOXYGUANOSINE, OR 2'3' -DIDEOXYADENOSINE) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIDEX EC
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0216510 | SPC/GB94/005 | United Kingdom | ⤷ Start Trial | SPC/GB94/005:, EXPIRES: 20070504 |
| 0216510 | 94C0006 | Belgium | ⤷ Start Trial | PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505 |
| 0285237 | 94C0006 | France | ⤷ Start Trial | PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505 |
| 0216510 | SZ 54/1994 | Austria | ⤷ Start Trial | PRODUCT NAME: 2',3'-DIDEOXYINOSIN |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch